




Lessening Organ Dysfunction with VITamin C

CONGRATULATIONS


Juravinski Hospital and Ottawa Civic have each enrolled their first participant into LOVIT-COVID.
 Thirteen sites are activated and 378 participants have been enrolled to date.

The DSMB reviewed data from the first LOVIT-COVID interim analysis (n=250).
 Upon reviewing the results of the LOVIT trial (under embargo), the DSMB requested an unplanned interim analysis of LOVIT-COVID (n=323).
The DSMB recommended continuation of the LOVIT-COVID trial.

Data Validation Summary by Site (as of April 11, 2022)



Please continue to enter data and answer queries in the database in a timely manner 😊
 Enrollment will continue until we reach the prespecified sample size of n=800 or until the combined analysis of the REMAP-CAP vitamin C domain and LOVIT-COVID meets prespecified stopping criteria, whichever comes first.



Marie-Hélène Masse
 Project leader
 1-819-346-1110 ext. 14173
marie-helene.masse3@usherbrooke.ca

Julie Ménard
 Co-Project leader
 1-819-346-1110 ext. 13534
julie.menard.ciussse-chus@ssss.gouv.qc.ca

Visit our website: <http://lovit.cctg.ca/>